Abcellera Biologics Inc (ABCL)

$3.49 +0.03 (0.87%)
Market Cap 1.04B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 3,362,100
Avg Vol 5,327,436
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 32%
Beta 0.73
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
Kaykay610
Kaykay610 Dec. 3 at 10:55 PM
$ABCL I've been reviewing bruker vs abcellera and abcellera's case looks strong!!! Next catalyst is bruker case results or licensing settlement. Jan 26 2026.
0 · Reply
DOGBIRD
DOGBIRD Dec. 3 at 8:53 PM
$ABCL Willing to buy at higher SP mid next year after data.
0 · Reply
Samb2344
Samb2344 Dec. 3 at 7:09 PM
$ABCL 🤌
0 · Reply
Ed_Ng
Ed_Ng Dec. 3 at 6:58 PM
$ABCL easy short ever!
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 3 at 5:55 PM
$ABCL MY TAKE : $ABCL doesnt move until tax loss selling is done @ Dec 10. Its basing here and could base until Jan. I hope it moves sooner but only the market knows...
0 · Reply
PorkchopSquats
PorkchopSquats Dec. 3 at 4:52 PM
$ABCL $PRME Don’t even need to retake the pic lmao.
1 · Reply
Ed_Ng
Ed_Ng Dec. 3 at 4:16 PM
$ABCL oh. Still lagging here 🗑️
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Dec. 3 at 2:03 PM
$ABCL Who is ready for today, loa up we are leaving 3 realm back up to 5 or 6 💥 💥 💥 💥 💥
0 · Reply
Bwill15
Bwill15 Dec. 3 at 12:27 AM
$ABCL snagged 10,000 shares for a starter
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 3 at 12:26 AM
$ABCL This is huge news 📰 $ABCL FDA draft guidance sharply reduces/eliminate NHP tox studies for most monospecific mAbs → ~$5-10M and 3-6 months saved per program. Same day new photos drop of AbCellera’s $700M CAD Vancouver AI-biologics campus (incl. $300M govt funding). Lower hurdles, faster INDs, major capacity expansion. Remains deeply undervalued.
0 · Reply
Latest News on ABCL
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 11 days ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 23 days ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 26 days ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 27 days ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 2 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 3 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 3 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 4 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Jun 2, 2025, 6:45 PM EDT - 6 months ago

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 7 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 7 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 7 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 7 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 7 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 7 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 9 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 9 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 11 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 11 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Jul 21, 2024, 5:37 AM EDT - 1 year ago

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

FATE

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Down 57%, Is AbCellera Biologics a Buy on the Dip?

Jun 13, 2024, 5:40 AM EDT - 1 year ago

Down 57%, Is AbCellera Biologics a Buy on the Dip?

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Kaykay610
Kaykay610 Dec. 3 at 10:55 PM
$ABCL I've been reviewing bruker vs abcellera and abcellera's case looks strong!!! Next catalyst is bruker case results or licensing settlement. Jan 26 2026.
0 · Reply
DOGBIRD
DOGBIRD Dec. 3 at 8:53 PM
$ABCL Willing to buy at higher SP mid next year after data.
0 · Reply
Samb2344
Samb2344 Dec. 3 at 7:09 PM
$ABCL 🤌
0 · Reply
Ed_Ng
Ed_Ng Dec. 3 at 6:58 PM
$ABCL easy short ever!
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 3 at 5:55 PM
$ABCL MY TAKE : $ABCL doesnt move until tax loss selling is done @ Dec 10. Its basing here and could base until Jan. I hope it moves sooner but only the market knows...
0 · Reply
PorkchopSquats
PorkchopSquats Dec. 3 at 4:52 PM
$ABCL $PRME Don’t even need to retake the pic lmao.
1 · Reply
Ed_Ng
Ed_Ng Dec. 3 at 4:16 PM
$ABCL oh. Still lagging here 🗑️
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Dec. 3 at 2:03 PM
$ABCL Who is ready for today, loa up we are leaving 3 realm back up to 5 or 6 💥 💥 💥 💥 💥
0 · Reply
Bwill15
Bwill15 Dec. 3 at 12:27 AM
$ABCL snagged 10,000 shares for a starter
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 3 at 12:26 AM
$ABCL This is huge news 📰 $ABCL FDA draft guidance sharply reduces/eliminate NHP tox studies for most monospecific mAbs → ~$5-10M and 3-6 months saved per program. Same day new photos drop of AbCellera’s $700M CAD Vancouver AI-biologics campus (incl. $300M govt funding). Lower hurdles, faster INDs, major capacity expansion. Remains deeply undervalued.
0 · Reply
Samb2344
Samb2344 Dec. 2 at 10:23 PM
$ABCL easy $6-$10 Plus stock stop tripping and eat dip
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 2 at 7:55 PM
$ABCL Great read; https://news.ubc.ca/2025/11/how-abcellera-grew-from-a-ubc-lab-to-a-global-biotech-company/
0 · Reply
OnChainAce
OnChainAce Dec. 2 at 7:21 PM
$ABCL fundamentals have changed at all. If anything, they’ve gotten even better. It’s the market that sucks. Adding more here is a no brainer
2 · Reply
Ed_Ng
Ed_Ng Dec. 2 at 6:38 PM
$ABCL still 🗑️
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 2 at 6:35 PM
$ABCL Bullish Abcellera $ABCL.
0 · Reply
tkstockpicker
tkstockpicker Dec. 2 at 3:57 PM
$ABCL Bought
0 · Reply
sogenerous
sogenerous Dec. 2 at 3:48 PM
$ABCL added some shares 3.4s
1 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 2 at 3:44 PM
$ABCL $ABCL new site. 👀 https://www.linkedin.com/posts/francl-architecture_creating-a-cutting-edge-bio-campus-hub-in-activity-7399144873712336896-GqsZ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAa-iaABIEAAl_d-VFoT3tr6jSwR2Y0JMnM
0 · Reply
Targhee
Targhee Dec. 2 at 3:08 PM
$ABCL
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 2 at 3:08 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ABCL Contracts: $ABCL January 15, 2027 $4 Calls Scale in: $1.53- $1.87 Scale out: $5.95-$10.20 Profit Potential : 231% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
DeMampCamp
DeMampCamp Dec. 2 at 3:05 PM
$ABCL It's usually green 99% of the time in premarket and then ALWAYS dumps at the open, it's been that way for years now. We lost any and all momentum this stock had thanks to the worst PR department in all of the stock market. Tax loss selling will likely keep this near where it's at is my guess until next year. Shifting my focus to other stocks for now until this shows some signs of life again :(
0 · Reply
tradersunion353
tradersunion353 Dec. 2 at 2:11 PM
$ABCL Sad to see this dropping $3 zone . Will give another year to see if this make it to $10
0 · Reply